Fifth Third Bancorp boosted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 8,130.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,052 shares of the company’s stock after buying an additional 28,699 shares during the quarter. Fifth Third Bancorp owned approximately 0.06% of Prestige Consumer Healthcare worth $1,722,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently made changes to their positions in the company. Norges Bank bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $36,954,000. Brandes Investment Partners LP raised its position in shares of Prestige Consumer Healthcare by 93.2% in the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after purchasing an additional 292,744 shares during the period. Capital Research Global Investors raised its position in shares of Prestige Consumer Healthcare by 107.9% in the fourth quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock valued at $34,639,000 after purchasing an additional 291,425 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Prestige Consumer Healthcare by 316.1% during the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock valued at $18,836,000 after buying an additional 229,311 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares during the period. 99.95% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Prestige Consumer Healthcare In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the sale, the vice president owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is currently owned by insiders.
Prestige Consumer Healthcare Stock Performance NYSE PBH opened at $48.91 on Thursday. The company’s 50 day simple moving average is $47.82 and its two-hundred day simple moving average is $57.04. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $77.45. The stock has a market capitalization of $2.32 billion, a PE ratio of 12.51, a P/E/G ratio of 1.58 and a beta of 0.35.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million for the quarter, compared to analysts’ expectations of $293.64 million. During the same quarter last year, the firm earned $1.32 earnings per share. The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.
Analyst Ratings Changes PBH has been the subject of a number of recent research reports. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group cut their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $70.75.
Read Our Latest Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare Company Profile (Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Stories Five stocks we like better than Prestige Consumer Healthcare Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report).
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of New York Mellon Corp Sells 631,362 Shares of BioMarin Pharmaceutical Inc. $BMRN
NEXT HEADLINE »Fifth Third Bancorp Raises Position in Reynolds Consumer Products Inc. $REYN
Bessemer Group Inc. raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 20.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 374,691 shares of the company’s stock after buying an additional 64,760 shares during the period. Bessemer Group Inc. owned about 0.79% of Prestige Consumer Healthcare worth $22,207,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in PBH. Lido Advisors LLC increased its holdings in shares of Prestige Consumer Healthcare by 5.4% during the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock worth $235,000 after acquiring an additional 192 shares during the last quarter. Cerity Partners LLC boosted its position in Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after purchasing an additional 218 shares during the period. UMB Bank n.a. boosted its position in Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in shares of Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its holdings in shares of Prestige Consumer Healthcare by 4.6% in the third quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after purchasing an additional 256 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.
Prestige Consumer Healthcare Stock Performance Shares of NYSE PBH opened at $49.92 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of 12.77, a P/E/G ratio of 1.60 and a beta of 0.35. The stock’s fifty day moving average price is $47.91 and its two-hundred day moving average price is $57.35. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $77.45.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm’s quarterly revenue was down 5.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.
Wall Street Analyst Weigh In A number of analysts have recently issued reports on the stock. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $70.75.
Get Our Latest Report on Prestige Consumer Healthcare
Insiders Place Their Bets In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by company insiders.
Prestige Consumer Healthcare Company Profile (Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Stories Five stocks we like better than Prestige Consumer Healthcare Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEProcter & Gamble Company (The) $PG Shares Bought by AIA Group Ltd
NEXT HEADLINE »Bessemer Group Inc. Grows Stock Holdings in Infosys Ltd. $INFY
On June 30, 2026, John Rogers (Trades, Portfolio) executed a notable transaction involving Prestige Consumer Healthcare Inc (PBH). The transaction saw an additi
Investors in Prestige Consumer Healthcare Inc. (PBH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 16, 2026 $45 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Prestige Consumer Healthcare shares, but what is the fundamental picture for the company? Currently, Prestige Consumer Healthcare is a Zacks Rank #5 (Strong Sell) in the Medical – Products industry that ranks in the Bottom 31% of our Zacks Industry Rank. Over the last 60 days, no analyst increased the earnings estimates for the current quarter, while two have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.05 per share to 89 cents in that period.
Given the way analysts feel about Prestige Consumer Healthcare right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026.
Completion of LaCorium Health Acquisition
The Company completed the acquisition on July 1, 2026. The closing was finalized pursuant to the terms of the definitive agreement announced on May 13, 2026, under which Prestige agreed to acquire LaCorium for approximately $150 million in cash. The Company financed the transaction with cash on hand and existing credit facilities.
Founded in Australia and introduced in 1998, LaCorium is a leader in Australian therapeutic skin care designed to treat individual skin ailments. Products are sold under the Dermal Therapy®, Flexitol®, and Crampeze® brands in need-state categories such as lip care (cold sores), skin care (eczema & acne), foot care (heel balm, antifungal), hair & scalp (eczema), and more. Approximately 75% of LaCorium’s sales are generated in Australia, where the brand holds the #1 market position in lip care and the #3 position in foot care.
LaCorium generates approximately $40 million in revenue annually and is expected to generate approximately $12 million in EBITDA, including the benefits from anticipated synergies, once the business is fully integrated. The Company expects LaCorium to deliver strong long-term revenue growth, supported by category growth, innovation, and continued geographic expansion.
Pricing of Senior Notes Offering
Prestige has also priced an offering of $400 million in aggregate principal amount of 6.25% senior notes due 2034 (the “notes”) in a private offering. The sale of the notes is expected to be completed on or about July 15, 2026, subject to customary closing conditions. The notes will be senior unsecured obligations of Prestige Brands, Inc. and will be guaranteed by the Company and certain of its domestic subsidiaries. The Company intends to use the net proceeds from the offering, together with cash on hand, to redeem all $400 million of Prestige’s’ outstanding 5.125% Senior Notes due January 2028, and to pay related fees and expenses. The change in interest expense is contemplated in Prestige’s medium-term outlook provided on May 13, 2026.
The notes and related guarantees are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes and related guarantees. Any offers of the notes and related guarantees will be made only by means of a private offering memorandum. The notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.
First Quarter Fiscal 2027 Earnings Call
The Company will issue its fiscal 2027 first quarter earnings release on Thursday, August 6, 2026 before the market open. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Note Regarding Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by the use of forward-looking terminology such as “expected,” “will,” and “intends” (or the negative or other derivatives of each of these terms) or similar terminology. The “forward-looking statements” include, without limitation, statements regarding the Company’s expectations regarding the completion of the sale of the notes and the redemption of the 2028 notes. These statements are based on management’s estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including general economic and business conditions. A discussion of other factors that could cause results to vary is included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819 [email protected]
When Alphabet joined the Dow Jones Industrial Average (^DJI +1.14%), the financial press couldn't stop talking about it. And when Warren Buffett's Berkshire Hathaway made it a top portfolio holding, that drumbeat got louder.
There's nothing wrong with owning Alphabet -- it's a great business. But the investors who've built real wealth over decades aren't always the ones chasing the loudest names. Sometimes it's the quiet compounders that win.
Prestige Consumer Healthcare (PBH +2.62%) is not a name you'll hear on CNBC. The company sells over-the-counter healthcare products like Monistat, Dramamine, Clear Eyes, Chloraseptic, and BC Powder. These brands live in medicine cabinets and bathroom drawers across North America. It's boring in the best possible way.
But something big just happened. On June 15, Prestige closed its largest acquisition in company history: the $1.045 billion purchase of the Breathe Right brand and several other OTC labels from Foundation Consumer Healthcare. Breathe Right -- the nasal strip that's been on athletes' faces and on nightstands next to CPAP machines for decades -- just became Prestige's single largest brand.
Today's Change
(
2.62
%) $
1.26
Current Price
$
49.42
The Breathe Right play The deal brings in roughly $200 million in annual revenue and $95 million in earnings before interest, taxes, depreciation, and amortization (EBITDA). It also includes Dimetapp, long the go-to children's cough and cold brand, and Anbesol for oral pain relief. But Breathe Right is the anchor.
What Prestige sees in that brand goes beyond the strip itself. Breathe Right has a foothold in sleep wellness, athletic performance, allergy relief, and congestion.
CEO Ron Lombardi pointed to the company's work with Dramamine as the blueprint. Prestige acquired Dramamine when it was thought of as strictly a motion sickness brand and then expanded it into a broader remedy for everyday nausea and vertigo. The Breathe Right playbook will likely look similar: invest in consumer awareness, broaden the use cases, and build the category.
That model has worked before. Historically, about 64% of Prestige's revenues come from brands that hold the No. 1 position in their categories. The company has spent years assembling a portfolio of what it calls "category synonymous" brands -- names so embedded in consumer memory that the brand name effectively is the category.
Image source: Getty Images.
A quieter GLP-1 angle One thing that doesn't get enough attention is that Prestige has been threading its portfolio into the GLP-1 conversation. As millions of Americans start using weight-loss medications like Ozempic and Wegovy, they're dealing with side effects that Prestige's brands are built for: nausea, digestive issues, and constipation.
The company has been marketing Dramamine and Fleet toward GLP-1 users seeking relief. That's a smart repositioning of existing assets. And it costs next to nothing compared to launching a new product.
Going international The Breathe Right deal isn't the only move this year. Prestige also announced an agreement to acquire LaCorium Health, a leading therapeutic skincare brand in Australia. The company already operates in Australia through its Hydralyte and Fess brands, so this deepens an existing footprint rather than planting a flag in unfamiliar territory.
International OTC healthcare represents a real runway. The markets are fragmented, consumer trust in established brands matters, and Prestige's asset-light model travels well.
The risk worth naming None of this comes free. The Breathe Right deal pushed Prestige's net leverage to roughly 4.0x EBITDA at closing. That's a real debt load, and the company needs its free cash flow to behave.
Management has projected a return below 3.0x leverage by fiscal 2028 -- but that assumes execution holds. Integration stumbles, a softening consumer, or a brand that doesn't respond to investment are all real possibilities here.
Prestige Consumer Healthcare isn't going to light up your portfolio overnight. What it offers is a business with category-leading brands, a repeatable acquisition model, and a fresh runway through Breathe Right. For investors willing to look past the big tech headlines, this OTC brand machine is worth a close look.
TARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $400 million in aggregate principal amount of new senior notes due 2034 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries.
The Company intends to use the net proceeds from the proposed offering, together with cash on hand, to redeem all $400 million of Prestige Brands’ outstanding 5.125% Senior Notes due 2028 (the “2028 notes”), and to pay related fees and expenses.
Prestige Brands expects to give notice of its intention to redeem the 2028 notes pursuant to the indenture governing the 2028 notes, at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest to the date of redemption. The redemption of the 2028 notes is conditioned on the completion of an offering of new unsecured senior notes in an aggregate principal amount of at least $400 million (the “Financing Condition”). Prestige Brands may waive the Financing Condition in its sole discretion.
The notes and related guarantees are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes and related guarantees. Any offers of the notes and related guarantees will be made only by means of a private offering memorandum. The notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat ® and Summer’s Eve ® women’s health products, BC ® and Goody’s ® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden’s ® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste ® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia.
Note Regarding Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by the use of forward-looking terminology such as “intends,” “expects,” “may,” and “will” (or the negative or other derivatives of each of these terms) or similar terminology. The “forward-looking statements” include, without limitation, statements regarding the Company’s expectations regarding the offering of the notes and the redemption of the 2028 notes. These statements are based on management’s estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including general economic and business conditions. A discussion of other factors that could cause results to vary is included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.
, /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company's disappointing Q4 2026 financial results.
The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
The firm encourages Prestige investors who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/pbh
Contact the Firm Now: [email protected]
844-916-0895
Prestige Consumer Healthcare Inc. (PBH) Investigation:
Prestige develops, manufactures, markets, sells, and distributes OTC health and personal care products to a wide range of customers. Clear Eyes®, a line of eye drops that provide cooling comfort and multi-symptom relief from redness, dryness, and itchiness is one of the company's major brands.
The investigation is focused on the propriety of Prestige's pre-May 14 disclosures concerning the performance of its recently acquired Pillar5 facility which the company touted as resolving persistent Clear Eyes® supply chain constraints and returning the brand to its leading market share position.
Investors' expectations were dashed on May 13, 2026. That day, Prestige reported that its Q4 2026 revenues came in 5% lower than the year earlier quarter and 6.4% lower than the previous quarter.
More concerning, as compared to Q4 2025, North America OTC Eye & Ear Care, the segment which Clear Eyes® falls within, reported a whopping 20.6% decrease in revenues while its International OTC reported an equally disturbing year-over-year 31.3% decrease. Similarly, these business' revenues were massively lower on a sequential basis.
During the company's earnings call the next day, management revealed that there were "Clear Eyes supply constraints" and said "as we've seen in the past of dealing with the previous owners and management at Pillar5, is what would start out as an expected one-week shutdown to do something turned into two weeks, would turn into three, which would turn into four as things either got more complex or the work got expanded[.]"
In response, the market quickly reacted, sending the price of Prestige shares significantly lower.
"Our investigation is focused on when Prestige and its management first became aware that the Pillar5 facility was not performing and whether they might have misled investors about progress in remediating Clear Eyes® supply issues," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in Prestige and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »
If you'd like more information and answers to other frequently asked questions about the firm's Prestige investigation, read more »
Whistleblowers: Persons with non-public information regarding Prestige should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SAN FRANCISCO, June 23, 2026 (GLOBE NEWSWIRE) -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company’s disappointing Q4 2026 financial results.
The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
The firm encourages Prestige investors who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/pbh
Contact the Firm Now: [email protected]
844-916-0895
Prestige Consumer Healthcare Inc. (PBH) Investigation:
Prestige develops, manufactures, markets, sells, and distributes OTC health and personal care products to a wide range of customers. Clear Eyes®, a line of eye drops that provide cooling comfort and multi-symptom relief from redness, dryness, and itchiness is one of the company’s major brands.
The investigation is focused on the propriety of Prestige’s pre-May 14 disclosures concerning the performance of its recently acquired Pillar5 facility which the company touted as resolving persistent Clear Eyes® supply chain constraints and returning the brand to its leading market share position.
Investors’ expectations were dashed on May 13, 2026. That day, Prestige reported that its Q4 2026 revenues came in 5% lower than the year earlier quarter and 6.4% lower than the previous quarter.
More concerning, as compared to Q4 2025, North America OTC Eye & Ear Care, the segment which Clear Eyes® falls within, reported a whopping 20.6% decrease in revenues while its International OTC reported an equally disturbing year-over-year 31.3% decrease. Similarly, these business’ revenues were massively lower on a sequential basis.
During the company’s earnings call the next day, management revealed that there were “Clear Eyes supply constraints” and said “as we’ve seen in the past of dealing with the previous owners and management at Pillar5, is what would start out as an expected one-week shutdown to do something turned into two weeks, would turn into three, which would turn into four as things either got more complex or the work got expanded[.]”
In response, the market quickly reacted, sending the price of Prestige shares significantly lower.
“Our investigation is focused on when Prestige and its management first became aware that the Pillar5 facility was not performing and whether they might have misled investors about progress in remediating Clear Eyes® supply issues,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
If you invested in Prestige and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »
If you’d like more information and answers to other frequently asked questions about the firm’s Prestige investigation, read more »
Whistleblowers: Persons with non-public information regarding Prestige should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of the Breathe Right® brand and certain other brands.
The closing was finalized pursuant to the terms of the asset purchase agreement, announced on March 20, 2026, under which Prestige agreed to acquire the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated tax benefits valued at $150 million. Breathe Right®, created in the 1990s, is an iconic #1 brand synonymous with the nasal strip category. It will become the company’s largest brand and represents expansion into a new category for Prestige.
The Company financed the transaction with a combination of available cash on hand and a completed financing of a new Term Loan B.
Further details regarding the transaction and benefits of Prestige are detailed in a presentation dated March 20, 2026 available on the Company’s website at https://ir.prestigebrands.com/.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PRESTIGE CONSUMER HEALTHCARE (PBH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 13, 2026, Prestige Consumer annou.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PRESTIGE CONSUMER HEALTHCARE (PBH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On May 13, 2026, Prestige Consumer announced fourth quarter and full year 2026 earnings, including that, "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year."
In the associated earnings call, the Company’s CEO Ron Lombardi revealed "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, shares of Prestige Consumer fell $5.88 per share, or 11.35%, to close at $45.93 on May 14, 2026.
Contact Us To Participate or Learn More:
If you purchased Prestige Consumer securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith continues its investigation on behalf of Prestige Consumer Healthcare (âPrestige Consumerâ or the âCompanyâ) (NYSE: [url=
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON PRESTIGE CONSUMER HEALTHCARE (PBH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On May 13, 2026, Prestige Consumer announced fourth quarter and full year 2026 earnings, including that, "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year."
In the associated earnings call, the Company’s CEO Ron Lombardi revealed "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, shares of Prestige Consumer fell $5.88 per share, or 11.35%, to close at $45.93 on May 14, 2026.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Prestige Consumer should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
LOS ANGELES, May 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or “the Company”) (NYSE: PBH) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Prestige released its Q4 and full year 2026 financial results on May 13, 2026. The Company revealed, "for fiscal 2026, revenues decreased 4.5% organically versus the prior year" and "total company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." Based on this news, shares of Prestige fell by 11.35% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335 [email protected]
www.schallfirm.com
New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Prestige Consumer Healthcare Inc. (NYSE: PBH) ("Prestige Consumer Healthcare Inc.") concerning potential violations of the federal securities laws.
During the Q3 FY 2026 earnings call, CEO Ron Lombardi stated that Prestige Consumer Healthcare anticipated a 57% adjusted gross margin in Q4. Management further projected projected free cash flow of $245 million or more for the full year alongside an adjusted EPS of $4.54. When Q4 results were reported, adjusted gross margin came in at approximately 55.4%, full-year free cash flow totaled $228 million, and adjusted diluted EPS was only 4.38; all three missed Prestige's internal projections.
Separately, Prestige Consumer Healthcare completed a $150 million acquisition of Australian skin-care firm LaCorium during the period. The acquisition was not discussed on the Q3 earnings call and was absent from the forward guidance framework presented to investors. PBH shares declined sharply following the Q4 disclosure.
If you suffered a loss on your Prestige Consumer Healthcare Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004 [email protected]
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298721
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that “for fiscal ‘26, revenues decreased 4.5% organically versus the prior year” and “[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year.” In the associated earnings call, the Company’s CEO Ron Lombardi revealed that “in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates.”
On this news, Prestige’s stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." In the associated earnings call, the Company's CEO Ron Lombardi revealed that "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, Prestige's stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Investors in Prestige Consumer Healthcare Inc. (PBH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 16, 2026 $45 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Prestige Consumer shares, but what is the fundamental picture for the company? Currently, Prestige Consumer is a Zacks Rank #4 (Sell) in the Medical – Products industry that ranks in the Bottom 33% of our Zacks Industry Rank. Over the last 60 days, no analyst increased their earnings estimates for the current quarter, while one has dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.05 per share to 96 cents in that period.
Given the way analysts feel about Prestige Consumer right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that “for fiscal ‘26, revenues decreased 4.5% organically versus the prior year” and “[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year.” In the associated earnings call, the Company’s CEO Ron Lombardi revealed that “in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates.”
On this news, Prestige’s stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." In the associated earnings call, the Company's CEO Ron Lombardi revealed that "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, Prestige's stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday, June 8, 2026 at 9:45 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:
For those unable to participate during the live webcast, a replay option will be available on the Company’s website following the event.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or "the Company") (NYSE: PBH) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Prestige released its Q4 and full year 2026 financial results on May 13, 2026. The Company revealed, "for fiscal 2026, revenues decreased 4.5% organically versus the prior year" and "total company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." Based on this news, shares of Prestige fell by 11.35% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that “for fiscal ‘26, revenues decreased 4.5% organically versus the prior year” and “[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year.” In the associated earnings call, the Company’s CEO Ron Lombardi revealed that “in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates.”
On this news, Prestige’s stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Amylyx Stock: Why the Full Pipeline Story MattersAmylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
Klee described avexitide as a first-in-class GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia, or PBH, a condition he said affects about 160,000 people in the U.S. He said the company expects that population to grow over time.
Get Amylyx Pharmaceuticals alerts:
3 small-cap biotechs with potential breakthroughs in 2024PBH is characterized by persistent, symptomatic severe hypoglycemia, Klee said, including neuroglycopenia, in which the brain does not receive enough glucose. He said patients can experience severe confusion, loss of consciousness and seizures, and that there are currently no approved treatments for the condition.
Klee said PBH is driven by elevated GLP-1 response after bariatric surgery, with some patients producing 10 to 20 times normal GLP-1 levels. That can cause insulin spikes and severe hypoglycemia. Avexitide is designed to block the GLP-1 receptor and reduce downstream hypoglycemia.
Phase 3 Readout Expected in Third Quarter These biotechs targeting multiple neurodegenerative diseasesKlee said Amylyx expects topline results from its Phase 3 pivotal trial of avexitide in the third quarter. The company completed enrollment at the end of March, and the study includes a 16-week double-blind, placebo-controlled period, followed by time for database cleaning, lock and analysis.
The Phase 3 trial is testing a 90 mg dose of avexitide. Klee said an earlier 60 mg dose showed effectiveness, but investigators observed possible breakthrough hypoglycemic events late at night or early in the morning. Pharmacokinetic analysis suggested coverage could be improved, leading to the higher dose.
He said the 90 mg dose provided coverage across the full day and night cycle in a Phase 2b trial, where the company observed reductions in both daytime and nighttime hypoglycemia as measured by continuous glucose monitoring, along with what he described as a good safety profile.
Klee said the Phase 3 trial was designed to be consistent with earlier studies, including the requirement that participants have frequent hypoglycemic events during a run-in period. He said the study is 90% powered to detect a 35% relative difference in Level 2 and Level 3 hypoglycemic events, compared with a 64% treatment effect observed in Phase 2b.
Trial Conduct and Endpoint Measurement Klee addressed investor questions about trial conduct, saying the primary endpoint is a composite of Level 2 and Level 3 hypoglycemic events. Level 2 events are measured by finger-stick blood glucose readings below 54 mg per deciliter, while Level 3 events involve the need for independent rescue.
Participants complete diary entries, and Level 3 events are reviewed by an adjudication committee of expert endocrinologists using a charter that Klee said was reviewed by the U.S. Food and Drug Administration. He also noted that FDA guidance recognizes the endpoint and that avexitide has received Breakthrough Therapy designation.
Klee said Amylyx can monitor trial data nearly in real time, including finger-stick readings, diaries and blinded continuous glucose monitor data. The company uses that information to assess whether participants are consistently capturing events and following study procedures.
He also discussed dietary behavior, saying participants are trained and retrained on diet, and must certify at every visit that they are following guidance. Klee said some diet liberalization occurred in earlier Phase 2 work, but that avexitide still produced a 55% reduction in hypoglycemic events in the first Phase 2 trial.
Commercial Planning Underway Klee said Amylyx is preparing for a potential launch in 2027 if the Phase 3 study is successful. He said the company is already working on its new drug application and pre-commercial activities.
He characterized PBH as a rare disease with significant unmet need and said Amylyx is seeing growing awareness among endocrinologists. Klee said PBH is now included on endocrinology board exams and that an ICD-10 code for PBH is expected to be adopted in October.
Current care is centered on medical nutrition therapy, Klee said, including frequent small meals and avoidance of simple carbohydrates. He said physicians use a variety of off-label medications, but said they do not address the GLP-1 mechanism that Amylyx believes is central to PBH.
Klee said Amylyx is refining its go-to-market strategy and expects to focus early efforts on centers that treat large numbers of PBH patients, including academic and large endocrinology centers. He said the company is thinking about its commercial infrastructure in a rare disease framework, including field teams and digital tools.
On pricing, Klee said there are no direct analogs for PBH, but cited recent rare endocrine drug launches as potential reference points. He said Amylyx expects to work with payers to support access.
Long-Acting GLP-1 Antagonist and ALS Pipeline Klee said Amylyx is also developing AMX0318, a potential once-weekly, long-acting GLP-1 receptor antagonist. The program is in IND-enabling studies, and the company’s goal is to move it into the clinic next year. Amylyx is developing the molecule through a collaboration with Gubra, which Klee described as an expert in peptide drug development.
He said avexitide’s composition claims extend to 2037 before potential patent term extension, which could add another two to three years. Klee said further innovation, including AMX0318, could support additional intellectual property.
Klee also discussed AMX0114, Amylyx’s calpain-2 program for ALS. The intrathecally administered antisense oligonucleotide is in a multiple ascending dose study in people with ALS. Klee said the company has completed the first two dosing cohorts, is moving to cohort 3 and plans to present biomarker results from the lowest-dose cohort at an ALS conference this month.
Cash Runway Into 2028 Klee said Amylyx has cash runway into 2028. He said that guidance includes work leading up to and through a potential 2027 commercialization of avexitide, including field team buildout, inventory and launch preparations intended to support access for PBH patients.
About Amylyx Pharmaceuticals NASDAQ: AMLXAmylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Amylyx Pharmaceuticals Right Now?Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." In the associated earnings call, the Company's CEO Ron Lombardi revealed that "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, Prestige's stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or "the Company") (NYSE: PBH) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Prestige released its Q4 and full year 2026 financial results on May 13, 2026. The Company revealed, "for fiscal 2026, revenues decreased 4.5% organically versus the prior year" and "total company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." Based on this news, shares of Prestige fell by 11.35% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
